The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Inclusion Criteria

• •Participants legally competent to sign and give informed consent
• •Males and females ages 18 years and older (inclusive)
• •Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator
• •Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.
• •In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
• •Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.